Skip to content
Screener

Apogee Therapeutics, Inc. APGE Operating Lease Liabilities

Operating Lease Liabilities at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$60.63M-22.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$11.49M-15.6%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$2.04M-10.1%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$4.89M-32.6%

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$10.17B+380%
Enterprise value$9.73B+385%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:20 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215698
Line itemMARCH 31,2026DECEMBER 31,2025
Accrued expenses and other current liabilities28,57723,181
Total current liabilities32,95227,906
Long-term liabilities:
Lease liability, net of current4,9095,345
Total liabilities37,86133,251
Commitments and contingencies (Note 9)
Stockholders' equity:
Common Stock; $0.00001 par value, 400,000,000 authorized, 75,323,726 issued and 74,882,396 outstanding as of March 31, 2026; 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 202511

Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)

FAQ

What is Apogee Therapeutics, Inc.'s operating lease liabilities?
Apogee Therapeutics, Inc. (APGE) reported operating lease liabilities of $4.91M in Q1 2026.
How has Apogee Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
Apogee Therapeutics, Inc.'s operating lease liabilities decreased by 37.4% year-over-year, from $7.84M to $4.91M.
What is the long-term trend for Apogee Therapeutics, Inc.'s operating lease liabilities?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s operating lease liabilities has grown at a 139.3% compound annual growth rate (CAGR), from $933K to $5.35M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Apogee Therapeutics, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude